| Renal-cell carcinoma RJ Motzer, NH Bander, DM Nanus New England Journal of Medicine 335 (12), 865-875, 1996 | 2308 | 1996 |
| Mutations of the VHL tumour suppressor gene in renal carcinoma JR Gnarra, K Tory, Y Weng, L Schmidt, MH Wei, H Li, F Latif, S Liu, ... Nature genetics 7 (1), 85-90, 1994 | 2042 | 1994 |
| Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile J Hrkach, D Von Hoff, MM Ali, E Andrianova, J Auer, T Campbell, ... Science translational medicine 4 (128), 128ra39-128ra39, 2012 | 1197 | 2012 |
| Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature SS Chang, VE Reuter, WDW Heston, NH Bander, LS Grauer, PB Gaudin Cancer research 59 (13), 3192-3198, 1999 | 1035 | 1999 |
| Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse CN Sternberg, A Yagoda, HI Scher, RC Watson, N Geller, HW Herr, ... Cancer 64 (12), 2448-2458, 1989 | 800 | 1989 |
| Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium H Liu, P Moy, S Kim, Y Xia, A Rajasekaran, V Navarro, B Knudsen, ... Cancer research 57 (17), 3629-3634, 1997 | 737 | 1997 |
| Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer NH Bander, MI Milowsky, DM Nanus, L Kostakoglu, S Vallabhajosula, ... Journal of Clinical Oncology 23 (21), 4591-4601, 2005 | 606 | 2005 |
| Tumor therapy with targeted atomic nanogenerators MR McDevitt, D Ma, LT Lai, J Simon, P Borchardt, RK Frank, K Wu, ... Science 294 (5546), 1537-1540, 2001 | 597 | 2001 |
| The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer D Chakravarty, A Sboner, SS Nair, E Giannopoulou, R Li, S Hennig, ... Nature communications 5 (1), 5383, 2014 | 591 | 2014 |
| Constitutive and antibody-induced internalization of prostate-specific membrane antigen H Liu, AK Rajasekaran, P Moy, Y Xia, S Kim, V Navarro, R Rahmati, ... Cancer research 58 (18), 4055-4060, 1998 | 585 | 1998 |
| M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium CN Sternberg, A Yagoda, HI Scher, RC Watson, HW Herr, MJ Morse, ... The Journal of urology 139 (3), 461-469, 1988 | 580 | 1988 |
| Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. M Mangin, AC Webb, BE Dreyer, JT Posillico, K Ikeda, EC Weir, ... Proceedings of the National Academy of Sciences 85 (2), 597-601, 1988 | 507 | 1988 |
| 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo JP Holland, V Divilov, NH Bander, PM Smith-Jones, SM Larson, JS Lewis Journal of Nuclear Medicine 51 (8), 1293-1300, 2010 | 488 | 2010 |
| Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer MS Darshan, MS Loftus, M Thadani-Mulero, BP Levy, D Escuin, XK Zhou, ... Cancer research 71 (18), 6019-6029, 2011 | 482 | 2011 |
| Phase II study of lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer ST Tagawa, MI Milowsky, M Morris, S Vallabhajosula, P Christos, ... Clinical cancer research 19 (18), 5182-5191, 2013 | 479 | 2013 |
| Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody JP Gleghorn, ED Pratt, D Denning, H Liu, NH Bander, ST Tagawa, ... Lab on a Chip 10 (1), 27-29, 2010 | 469 | 2010 |
| Phase I trial of yttrium-90—labeled anti—prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer MI Milowsky, DM Nanus, L Kostakoglu, S Vallabhajosula, SJ Goldsmith, ... Journal of clinical oncology 22 (13), 2522-2531, 2004 | 369 | 2004 |
| Superparamagnetic iron oxide nanoparticle–aptamer bioconjugates for combined prostate cancer imaging and therapy AZ Wang, V Bagalkot, CC Vasilliou, F Gu, F Alexis, L Zhang, M Shaikh, ... ChemMedChem 3 (9), 1311, 2008 | 366 | 2008 |
| Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen MJ Evans, PM Smith-Jones, J Wongvipat, V Navarro, S Kim, NH Bander, ... Proceedings of the National Academy of Sciences 108 (23), 9578-9582, 2011 | 362 | 2011 |
| Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific … MC Gong, JB Latouche, A Krause, WDW Heston, NH Bander, M Sadelain Neoplasia 1 (2), 123-127, 1999 | 356 | 1999 |
